Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/101883
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Duong, M. | - |
dc.contributor.author | Nicholls, S. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Current Medicinal Chemistry, 2014; 21(25):2947-2951 | - |
dc.identifier.issn | 0929-8673 | - |
dc.identifier.issn | 1875-533X | - |
dc.identifier.uri | http://hdl.handle.net/2440/101883 | - |
dc.description.abstract | For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed. | - |
dc.description.statementofresponsibility | MyNgan Duong and Stephen J. Nicholls | - |
dc.language.iso | en | - |
dc.publisher | Bentham Science Publishers | - |
dc.rights | © 2016 Bentham Science Publishers | - |
dc.source.uri | http://dx.doi.org/10.2174/0929867321666140414104130 | - |
dc.subject | Atherosclerosis; cardiovascular disease; HDL; lipids; risk factors | - |
dc.title | New drugs for HDL-C disorders: the beginning | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.2174/0929867321666140414104130 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Duong, M. [0000-0002-9542-1187] | - |
dc.identifier.orcid | Nicholls, S. [0000-0002-9668-4368] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.